CLINICAL_TRIALS
trial_result
· 2017-10-11
Clinical Trial Update: Hip Fracture Study of GSK576428 (Fondaparinux Sodium) [Phase 3]
Summary
Phase 3 trial update for fondaparinux sodium (GSK576428) in a hip fracture study; results posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Thromboembolism | Phase 3 | Status: COMPLETED | Results posted: 2017-10-11